Managing Hemophilia for Life

Optimizing responses to therapy in hemophilia B: treatment individualization in an era of expanding options

Monday 22nd June 2015, 12:15–13:45
Room 716, Level 700, Metro Toronto Convention Centre, Toronto, Canada
Chair: Alfonso Iorio (Canada)
Managing Hemophilia for Life
Optimizing responses to therapy in hemophilia B: treatment individualization in an era of expanding options

Monday 22nd June 2015, 12:15–13:45
Room 716, Level 700, Metro Toronto Convention Centre, Toronto, Canada

12:15 Welcome and introduction
Chair: Alfonso Iorio (Canada)

12:20 Review of new Phase III data for BeneF®ix®: once-weekly prophylactic dosing in hemophilia B
Michael Tarantino (USA)

12:40 Review of new Phase III data for BeneF®ix®: additional analysis
Bartholomew Tortella (Pfizer)

12:50 Investigating the science behind FIX in the extravascular space
Darrel Stafford (USA)

13:10 Patient-centered approaches to dosing: treatment individualization with PK modeling
Alfonso Iorio (Canada)

13:30 Panel discussion
Moderated by Chair

13:40 Meeting summary and close

Dear Colleague,

It is with great pleasure that I welcome you to Toronto and invite you to join us for this symposium being held during the ISTH 2015 Congress:

Managing Hemophilia for Life
Optimizing responses to therapy in hemophilia B: treatment individualization in an era of expanding options

In recent years, individualizing treatment options for people with hemophilia has been a growing field of research, particularly in the area of pharmacokinetic approaches to optimizing prophylaxis. Despite significant advances in this field, further work is required, particularly in the area of hemophilia B, in order to fully understand its unique science and the complexity of Factor IX pharmacokinetics. Further developments in this area, along with a better understanding of the ways in which to use products specific to the individual needs of patients, have the potential to improve our ability to effectively personalize treatment.

This symposium will provide a unique opportunity to explore patient-centered approaches to individualizing treatment for hemophilia B in order to optimize patient outcomes.

We hope you can join us at what promises to be a stimulating and valuable symposium.

Alfonso Iorio
(McMaster University, Ontario, Canada)